SG11201804721SA - Modulators of complement activity - Google Patents

Modulators of complement activity

Info

Publication number
SG11201804721SA
SG11201804721SA SG11201804721SA SG11201804721SA SG11201804721SA SG 11201804721S A SG11201804721S A SG 11201804721SA SG 11201804721S A SG11201804721S A SG 11201804721SA SG 11201804721S A SG11201804721S A SG 11201804721SA SG 11201804721S A SG11201804721S A SG 11201804721SA
Authority
SG
Singapore
Prior art keywords
massachusetts
international
modulators
cambridge
pct
Prior art date
Application number
SG11201804721SA
Other languages
English (en)
Inventor
Steven James Demarco
Michelle Denise Hoarty
Grace Victoria Parker
Alonso Ricardo
Sylvia Tobe
Douglas A Treco
Original Assignee
Ra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ra Pharmaceuticals Inc filed Critical Ra Pharmaceuticals Inc
Publication of SG11201804721SA publication Critical patent/SG11201804721SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/30—Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or carpules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
SG11201804721SA 2015-12-16 2016-12-07 Modulators of complement activity SG11201804721SA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562268360P 2015-12-16 2015-12-16
US201662331320P 2016-05-03 2016-05-03
US201662347486P 2016-06-08 2016-06-08
PCT/US2016/065228 WO2017105939A1 (en) 2015-12-16 2016-12-07 Modulators of complement activity

Publications (1)

Publication Number Publication Date
SG11201804721SA true SG11201804721SA (en) 2018-07-30

Family

ID=57758701

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201804721SA SG11201804721SA (en) 2015-12-16 2016-12-07 Modulators of complement activity

Country Status (25)

Country Link
US (2) US10835574B2 (da)
EP (3) EP3389692B1 (da)
JP (3) JP7126940B2 (da)
KR (1) KR20180094913A (da)
CN (2) CN115920000A (da)
AU (1) AU2016370210A1 (da)
BR (1) BR112018012174A2 (da)
CA (1) CA3007772A1 (da)
CY (1) CY1123031T1 (da)
DK (2) DK3685847T3 (da)
ES (2) ES2941640T3 (da)
FI (1) FI3685847T3 (da)
HR (2) HRP20230182T1 (da)
HU (1) HUE061759T2 (da)
IL (1) IL259762B (da)
LT (2) LT3685847T (da)
MX (2) MX2018007352A (da)
PL (2) PL3389692T3 (da)
PT (2) PT3685847T (da)
RS (2) RS60134B1 (da)
RU (2) RU2733720C2 (da)
SG (1) SG11201804721SA (da)
SI (2) SI3685847T1 (da)
TW (2) TWI779805B (da)
WO (1) WO2017105939A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016029076B1 (pt) 2014-06-12 2024-02-15 Ra Pharmaceuticals, Inc Polipeptídeo e composição compreendendo o mesmo para inibir a clivagem de c5 em um sistema celular
PL3250230T3 (pl) 2015-01-28 2022-02-14 Ra Pharmaceuticals, Inc. Modulatory aktywności dopełniacza
CA3007772A1 (en) 2015-12-16 2017-06-22 Ra Pharmaceuticals, Inc. Modulators of complement activity
MX2019006527A (es) * 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
US20210000927A1 (en) 2017-12-04 2021-01-07 Ra Pharmaceuticals, Inc. Modulators of complement activity
CA3131927A1 (en) 2019-03-08 2020-09-17 Ra Pharmaceuticals, Inc. Modulators of complement activity
AU2020261059A1 (en) * 2019-04-24 2021-10-14 Ra Pharmaceuticals, Inc. Compositions and methods for modulating complement activity
WO2020247607A1 (en) 2019-06-04 2020-12-10 Ra Pharmaceuticals, Inc. Inflammatory disease treatment with complement inhibitors
EP4028126A1 (en) 2019-09-12 2022-07-20 RA Pharmaceuticals, Inc. Neurological disease treatment with complement inhibitors
IL297680A (en) 2020-04-30 2022-12-01 Alnylam Pharmaceuticals Inc IRNA compounds complement factor b (cfb) and methods of using them
AR127477A1 (es) 2021-10-29 2024-01-31 Alnylam Pharmaceuticals Inc COMPOSICIONES DE ARNi CONTRA EL FACTOR B DEL COMPLEMENTO (CFB) Y MÉTODOS DE USO DE LAS MISMAS

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271068A (en) 1968-05-10 1981-06-02 Ciba-Geigy Corporation Process for the manufacture of cystine-containing peptides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4033940A (en) 1975-11-12 1977-07-05 Armour Pharmaceutical Company Cyclization of peptides
US4216141A (en) 1978-07-19 1980-08-05 The Salk Institute For Biological Studies Method for cyclization of peptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5371109A (en) 1986-07-01 1994-12-06 Drilletten Ab Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0494955B1 (en) 1989-10-05 1998-07-15 Optein, Inc. Cell-free synthesis and isolation of novel genes and polypeptides
US5585353A (en) 1990-02-02 1996-12-17 The Rockefeller University Antibiotic peptides containing D-amino acids
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5843701A (en) 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
JPH08510325A (ja) 1993-05-28 1996-10-29 カイロン コーポレイション 生物学的に活性なペプチド配列の選択方法
EP0710243B1 (en) 1993-06-29 2000-06-14 Ferring B.V. Synthesis of cyclic peptides
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5834318A (en) 1995-05-10 1998-11-10 Bayer Corporation Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US6720472B2 (en) 1996-07-12 2004-04-13 University Of Medicine And Dentistry Of New Jersey HMGI proteins in cancer and obesity
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
WO1998016636A1 (fr) 1996-10-17 1998-04-23 Mitsubishi Chemical Corporation Molecule permettant d'homologuer un genotype et un phenotype, et utilisation de celle-ci
US5922680A (en) 1996-10-23 1999-07-13 Ferring, B.V. Stabilized composition for oral administration of peptides
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
ATE529509T1 (de) 1997-01-21 2011-11-15 Gen Hospital Corp Selektion von proteinen unter verwendung von rna- protein-fusionen
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
EP0896001A1 (en) 1997-08-08 1999-02-10 Daicel Chemical Industries, Ltd. Method for preparing oxytocin antagoniste derivatives, intermediates for the preparation of oxytocin antagonist derivatives and method for preparing the intermediates
US6429301B1 (en) 1998-04-17 2002-08-06 Whitehead Institute For Biomedical Research Use of a ribozyme to join nucleic acids and peptides
JP4430235B2 (ja) 1998-08-07 2010-03-10 エミスフェアー・テクノロジーズ・インク 活性剤のデリバリーのための化合物及び組成物
AU1705100A (en) 1998-10-09 2000-05-01 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
US6962781B1 (en) 2000-05-19 2005-11-08 Proteonova, Inc. In vitro evolution of nucleic acids and encoded polypeptide
US7244701B2 (en) 2000-06-16 2007-07-17 Zealand Phama A/S Diuretic peptide conjugate
CA2524534C (en) 2003-05-15 2012-12-11 Sek Chung Fung Methods and compositions for the prevention and treatment of sepsis
EP1667702A2 (en) 2003-09-10 2006-06-14 Baxter International Inc., Baxter Healthcare Corp. Peptides that inhibit complement activation
CA2537029C (en) 2003-11-26 2013-03-12 Likan Liang Micellar systems useful for delivery of lipophilic or hydrophobic compounds
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
WO2006066258A2 (en) 2004-12-17 2006-06-22 Neose Technologies, Inc. Lipoconjugation of peptides
EP1844337B1 (en) 2005-01-24 2013-07-03 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics
WO2006105214A2 (en) 2005-03-29 2006-10-05 Cardax Pharmaceuticals, Inc. Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
EP1885398B1 (en) 2005-05-26 2015-07-08 The Regents of the University of Colorado, a body corporate Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
EP1888031B1 (en) 2005-06-06 2013-01-23 Camurus Ab Glp-1 analogue formulations
MY151064A (en) 2005-11-04 2014-03-31 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
MX340784B (es) * 2006-03-15 2016-07-26 Alexion Pharma Inc Inhibidores de complemento para usarse en el tratamiento de pacientes con hemoglobinuria paroxística nocturna.
EP1876183A1 (en) 2006-07-04 2008-01-09 Technische Universität München Minimized small peptides with high affinity for factor VIII and factor VIII-like proteins
HUE026042T2 (en) 2006-10-10 2016-05-30 Regenesance B V Complement inhibition for improved nerve regeneration
US7736860B2 (en) 2006-11-09 2010-06-15 Univeristy Of Massachusetts Methods of identifying compounds for the treatment of sterile inflammation
AU2008228247A1 (en) 2007-03-22 2008-09-25 Novartis Ag C5 antigens and uses thereof
US20100015139A1 (en) 2008-07-10 2010-01-21 Rekha Bansal METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
RU2009144142A (ru) 2007-04-30 2011-06-10 Алькон Рисерч, Лтд. (Us) Лечение возрастной дегенерации желтого пятна с применением ингибиторов фактора d комплемента
BRPI0812767A2 (pt) 2007-06-07 2014-12-02 Genentech Inc Anticorpos para c3b e métodos para prevenção e tratamento de distúrbios associados ao complemento
WO2009014633A1 (en) 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
CA2701470A1 (en) 2007-10-02 2009-04-09 Potentia Pharmaceuticals, Inc. Sustained delivery of compstatin analogs from gels
WO2009067191A2 (en) 2007-11-16 2009-05-28 The General Hospital Corporation Methods and compositions for the treatment of hepatitis c virus (hcv) infection
EP2278987A4 (en) 2008-03-28 2012-08-22 Apellis Ag MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM
US20100093624A1 (en) 2008-07-30 2010-04-15 Cosmix Therapeutics Llc Peptide therapeutics that bind vegf and methods of use thereof
WO2010025510A1 (en) 2008-09-03 2010-03-11 Xenome Ltd Libraries of peptide conjugates and methods for making them
CN109045296A (zh) 2008-11-10 2018-12-21 阿雷克森制药公司 用于治疗补体相关障碍的方法和组合物
AU2009230735B1 (en) 2009-01-08 2010-01-21 Shane Ramodien Electronic equipment housing
KR101788040B1 (ko) 2009-10-16 2017-10-19 오메로스 코포레이션 Ｍａｓｐ－2 의존성 보체 활성화의 억제에 의한 파종성 혈관내 응고의 치료 방법
CA2795311A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
US9358266B2 (en) 2010-02-25 2016-06-07 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
US20110269807A1 (en) 2010-04-30 2011-11-03 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
TW201241008A (en) * 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
CA2831563A1 (en) * 2011-03-29 2012-10-04 Abbvie Inc. Improved shroud deployment in automatic injection devices
EP2694108B1 (en) 2011-04-08 2018-06-06 University Of Leicester Methods for treating conditions associated with masp-2 dependent complement activation
AU2012250614B2 (en) * 2011-05-05 2016-02-11 Pharma Cinq, Llc Complement factor B analogs and their uses
WO2012162215A1 (en) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion of fracture healing using complement inhibitors
WO2012174055A1 (en) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Wound healing using complement inhibitors
CN102321170B (zh) 2011-09-14 2013-11-13 深圳翰宇药业股份有限公司 利拉鲁肽变构体及其缀合物
WO2013052736A2 (en) 2011-10-06 2013-04-11 The Medicines Company Methods of treating or preventing blood loss during surgery using the serine protease inhibitor mdco-2010
NZ628625A (en) 2012-02-20 2016-03-31 Swedish Orphan Biovitrum Ab Publ Polypeptides binding to human complement c5
US20130246083A1 (en) 2012-03-16 2013-09-19 Alexion Pharmaceuticals, Inc. Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
WO2013172954A1 (en) * 2012-05-17 2013-11-21 Ra Pharmaceuticals, Inc Peptide and peptidomimetic inhibitors
US9579360B2 (en) 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
US20130345257A1 (en) 2012-06-26 2013-12-26 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
US20150330989A1 (en) 2012-11-15 2015-11-19 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
US9700633B2 (en) 2013-01-28 2017-07-11 Jenkem Technology Co., Ltd., Tianjin Branch Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
US20140234275A1 (en) 2013-02-15 2014-08-21 Jason Williams Method for treating als via the increased production of factor h
US20150057342A1 (en) 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
CN104231085B (zh) * 2013-09-05 2017-03-15 复旦大学附属肿瘤医院 靶向特异性补体系统抑制剂、其制备方法及应用
CN106132982A (zh) 2014-03-20 2016-11-16 因弗拉克斯有限责任公司 用于治疗病毒性肺炎的C5a抑制剂
BR112016029076B1 (pt) 2014-06-12 2024-02-15 Ra Pharmaceuticals, Inc Polipeptídeo e composição compreendendo o mesmo para inibir a clivagem de c5 em um sistema celular
US20160168237A1 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
GB2541835B (en) 2015-01-21 2018-09-12 Pacira Pharmaceuticals Inc Multivesicular liposome formulations of tranexamic acid
PL3250230T3 (pl) * 2015-01-28 2022-02-14 Ra Pharmaceuticals, Inc. Modulatory aktywności dopełniacza
WO2017035362A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
CA3007772A1 (en) 2015-12-16 2017-06-22 Ra Pharmaceuticals, Inc. Modulators of complement activity
MX2019006527A (es) * 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
EP3682016A4 (en) 2017-09-11 2021-06-02 RA Pharmaceuticals, Inc. FORMULATIONS FOR ADMINISTERING COMPOUNDS
US20210000927A1 (en) 2017-12-04 2021-01-07 Ra Pharmaceuticals, Inc. Modulators of complement activity
CA3131927A1 (en) 2019-03-08 2020-09-17 Ra Pharmaceuticals, Inc. Modulators of complement activity
AU2020261059A1 (en) 2019-04-24 2021-10-14 Ra Pharmaceuticals, Inc. Compositions and methods for modulating complement activity

Also Published As

Publication number Publication date
TWI745320B (zh) 2021-11-11
SI3685847T1 (sl) 2023-05-31
RU2018121615A3 (da) 2020-03-16
LT3389692T (lt) 2020-04-27
RU2020131790A3 (da) 2021-11-18
LT3685847T (lt) 2023-03-27
RS64067B1 (sr) 2023-04-28
TWI779805B (zh) 2022-10-01
DK3389692T3 (da) 2020-03-30
MX2022013454A (es) 2023-02-22
SI3389692T1 (sl) 2020-07-31
RU2018121615A (ru) 2020-01-20
IL259762B (en) 2020-06-30
CY1123031T1 (el) 2021-10-29
RU2020131790A (ru) 2020-10-20
KR20180094913A (ko) 2018-08-24
EP3685847B1 (en) 2023-01-11
CN108697759B (zh) 2022-08-02
PT3685847T (pt) 2023-03-14
EP3389692B1 (en) 2020-03-04
TW202200189A (zh) 2022-01-01
HRP20200508T1 (hr) 2020-09-04
EP3389692A1 (en) 2018-10-24
US11752190B2 (en) 2023-09-12
BR112018012174A2 (pt) 2018-12-04
CN115920000A (zh) 2023-04-07
EP4218790A8 (en) 2023-10-04
CN108697759A (zh) 2018-10-23
WO2017105939A1 (en) 2017-06-22
US20210077572A1 (en) 2021-03-18
RS60134B1 (sr) 2020-05-29
EP4218790A1 (en) 2023-08-02
MX2018007352A (es) 2019-05-16
FI3685847T3 (fi) 2023-04-03
JP2024001300A (ja) 2024-01-09
JP2019504012A (ja) 2019-02-14
US20180369322A1 (en) 2018-12-27
IL259762A (en) 2018-07-31
JP7379615B2 (ja) 2023-11-14
RU2733720C2 (ru) 2020-10-06
RU2769701C2 (ru) 2022-04-05
EP3685847A1 (en) 2020-07-29
JP7126940B2 (ja) 2022-08-29
DK3685847T3 (da) 2023-02-27
CA3007772A1 (en) 2017-06-22
HRP20230182T1 (hr) 2023-04-14
PL3389692T3 (pl) 2020-06-15
ES2941640T3 (es) 2023-05-24
JP2022159479A (ja) 2022-10-17
HUE061759T2 (hu) 2023-08-28
AU2016370210A1 (en) 2018-06-21
US10835574B2 (en) 2020-11-17
ES2781551T3 (es) 2020-09-03
PL3685847T3 (pl) 2023-05-08
PT3389692T (pt) 2020-04-07
TW201733609A (zh) 2017-10-01

Similar Documents

Publication Publication Date Title
SG11201804721SA (en) Modulators of complement activity
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201808076UA (en) Facilitating vehicle driving and self-driving
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201810466PA (en) Compositions and methods related to engineered fc constructs
SG11201808552XA (en) T-cell modulatory multimeric polypeptides and methods of use thereof
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201807720TA (en) Methods and systems for determining antibiotic susceptibility
SG11201906959RA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201906163TA (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201909224QA (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
SG11201908678XA (en) Methods and compositions for reduction of immunogenicity
SG11201807596YA (en) Gitr antibodies, methods, and uses
SG11201806133UA (en) Intermediates in the synthesis of eribulin and related methods of synthesis
SG11201903885RA (en) Secure key management
SG11201906139VA (en) Compositions and methods related to engineered fc constructs
SG11201806127XA (en) Pharmaceutical or nutritional combination comprising beta-hydroxy-betamethylbutyrate